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Abstract 
Objectives: To systematically review all available evidence on efficacy and 
safety of cannabinoids for treating neurogenic lower urinary tract dysfunction 
(NLUTD) in patients with multiple sclerosis (MS). 
Patients and methods: The review was performed according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement. Studies were identified by electronic search of Cochrane register, 
Embase, Medline, Scopus (last search on 11 November 2016). 
Results: After screening 8469 articles, two randomized controlled trials and one 
open label study enrolling a total of 426 patients, were included. Cannabinoids 
relevantly decreased incontinence episodes in all three studies. Pooling data 
showed mean difference in incontinence episodes per 24 hours to be -0.35 
(95% confidence interval -0.46 to -0.24). Mild adverse events were frequent (38-
100%), but only two patients (0.7%) reported a serious adverse event. 
Conclusions: Preliminary data imply, that cannabinoids might be an effective 
and safe treatment option for NULTD in patients with MS. However, evidence 
base is poor and more high-quality, well-designed, adequately powered and 
sampled studies are urgently needed to reach definitive conclusions.  
1. Introduction 
Neurogenic lower urinary tract dysfunction (NLUTD) is highly prevalent in 
patients with multiple sclerosis (MS) and substantially impairs quality of life (1, 
2). The prevalence of NLUTD appears to be related to the duration of MS and is 
reported by almost all patients suffering from MS for more than 10 years (1, 3). 
Treatment of NLUTD in the MS population is a significant challenge, especially 
since standard therapies often fail. Thus, therapeutic alternatives are urgently 
needed. 
Cannabinoids, a heterogenous group of endogenous molecules and others that 
are metabolites of phytocannabinoids (4), were reported to improve tremor and 
spasticity in animal models (5) and questionnaire-based reports suggested 
beneficial effects of recreational cannabis use in patients with MS suffering from 
NLUTD (6). Cannabinoids are presumed to reduce detrusor contractility via 
cannabinoid receptors (7, 8) expressed both in the detrusor and central nervous 
system (9). However, cannabinoid-mediated actions on lower urinary tract 
function are complex and not yet fully understood. Considering the potential of 
cannabinoids for medical use (10), we performed a systematic review to assess 
and appraise the evidence on efficacy and safety of cannabinoids in the 
treatment of NLUTD in patients with MS. 
  
2.  Evidence acquisition 
 
2.1  Data sources and searches 
This systematic review was performed according to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement (11). A 
review protocol was elaborated, which is available on PROSPERO 
(CRD42014010142) (http://www.crd.york.ac.uk/PROSPERO). We 
systematically searched Cochrane Central Register of Controlled Trials, 
Embase, Medline, and Scopus from 1 January 1946 to 11 November 2016. No 
language restriction was applied. We additionally searched the reference lists of 
all included studies and any relevant review articles. Moreover, we looked for 
(on 23 November 2016) unpublished (ongoing) research in ClinicalTrials.gov 
and the ISRCTN registry, but no additional studies have been identified. The 
search strategies are illustrated in Web supplement 1. 
 
2.2 Study selection 
We aimed to include all original studies that reported efficacy and/or safety data 
on cannabinoids for treating NLUTD in female and male patients with MS, 
including randomized controlled trials (RCTs), comparative non-RCTs, and 
single-arm cohort studies. Non-original articles, those including children only, 
and those not discriminating between patients with MS and other 
neurological/non-neurological disorders were excluded. All identified abstracts 
were imported into bibliography management software (EndNote X7, Thomson 
Reuters, 1500 Spring Garden Street, Fourth Floor Philadelphia, PA 19130, 
USA) and filed according to inclusion and exclusion folders by drag and drop. 
Abstracts of all identified studies were independently reviewed by two authors 
(NAY, MPS and LM). Studies reporting on cannabinoids for treating NLUTD in 
patients with MS were reviewed in full text. 
 
2.3 Data extraction and risk of bias assessment 
The variables assessed included year of publication, type of study, type of 
cannabinoid, type of combination of cannabinoid, treatment duration, number of 
patients, gender and age, improvement of incontinence and nocturia episodes, 
number of daytime voids, adverse events and withdrawals. Data from eligible 
reports were extracted in duplicate (NAY and MPS) and discrepancies were 
resolved by a third reviewer (TMK). 
The Cochrane Risk of Bias Assessment tool was used for RCTs (12). This 
included the assessment of sequence generation, allocation concealment, 
blinding of participants, therapists, and outcome assessors, completeness of 
outcome data, and selective outcome reporting (Web supplement 2). The risk of 
bias in the comparative non-RCT was assessed using the Cochrane tool and an 
extra item to estimate the risk of findings being explained by confounding (Web 
supplement 2). This is a pragmatic approach recommended by methodological 
literature to assess risks of bias in non-randomized studies (13-15). A list of the 
5 most important confounders for efficacy and safety outcomes was developed 
with clinical content experts (members of the International Continence Society 
Neuro-Urology Promotion Committee). The confounding factors are gender, 
age, urinary tract infections, degree of disability (Expanded Disability Status 
Scale (EDSS) / duration of neurological disease) and other medications. In 
addition, external validity was taken into account by assessing whether study 
participants were selected consecutively and whether the specified confounding 
factors were comparable between the treatment groups. Attrition bias and 
selective outcome reporting were also assessed (Web supplement 2). This is 
also a pragmatic approach informed by the methodological literature (12). 
Finally, conflict of interest declaration, reporting of funding source and role of 
funding source was investigated. 
 
2.4 Data synthesis 
We constructed two-by-two tables for each of the included studies and 
calculated the effect size (ES) and corresponding 95% confidence intervals (CI). 
Since data were sparse, we performed only an exploratory analysis, ignoring 
differences in study design. The missing control group of the open label study 
was replaced by a norm-control group, generated by the mean values of the 
two control groups from the RCTs. We pooled the effect size using a random 
effects model. Forest plots were generated in order to provide a visual 
representation of results and to illustrate the direction and magnitude of effects. 
Analyses were performed using the metan command of the Stata statistics 
software package (Stata 14.0 and 9.0 statistics software package; StataCorp 
2009. Stata Statistical Software: Release 14. College Station, TX: StataCorp 
LP). 
Risk of bias summary and graph (Web supplement 2) was generated using 
Cochrane RevMan software (RevMan v 5.3; Informatics and Knowledge 
Management Department; Cochrane, St Albans House, 57-59 Haymarket, 
London, UK).  
3. Evidence synthesis 
 
3.1 Search results 
The PRISMA flow diagram chart (Figure 1) illustrates the literature search and 
results. After screening of 8469 abstracts, 3 studies have been included in the 
qualitative and quantitative synthesis. 
 
3.2 Study and patient characteristics (Table 1) 
Two of the 3 included studies, were RCTs (16, 17) and one was an open label 
study (18). Overall, the 3 included studies enrolled a total of 426 patients: 289 
women (68%), 122 men (29%), and 15 (3%) patients where the gender was not 
reported. The study by Brady et al. (18) was an open label study with a two 
phased follow up: initial combination therapy with 9-tetrahydrocannabinol (THC) 
and cannabidiol (CBD) for eight weeks, followed by a single THC-only therapy 
for further eight weeks. 
 
3.3 Efficacy of cannabinoids 
Cannabinoids relevantly decreased incontinence episodes in all three studies 
(Table 2). Pooling data showed mean difference in incontinence episodes per 
24 hours to be -0.35 (95% confidence interval -0.46 to -0.24) (Figure 2). In 
addition, a significant decrease of nocturia episodes, number of daytime voids 
and number of voids per 24 hours was found in one study (Table 2). 
 
3.4 Safety of cannabinoids 
The most common adverse events are illustrated in Table 1. The general 
number of mild adverse events was high (38-100%), but only two patients 
(0.7%, 2/277 patients) reported a serious adverse event (one haemorrhagic 
cystitis and one possible transient ischaemic attack, both with unclear 
causality). 
 
3.5 Risk of bias and confounding 
The risk of bias and confounding was high in the non-RCT (18) (Web 
supplement 2). 
 
3.6 Conflict of interest, funding source and role of founding source  
Conflict of interest was only disclosed by Kavia et al. (16). Non-company 
funding was reported by Brady et al. (18) and by Freeman et al. (17), whereas 
the study by Kavia et al. (16) was fully funded by the manufacturer company. 
None of the studies reported on the role of the founding source. 
  
4. Discussion 
 
4.1 Principal findings 
Improvements in incontinence rates, nocturia, daytime and 24-hour voids, as 
well as a limited number of severe adverse events suggest that cannabinoids 
may be effective and safe for treating NLUTD in patients with MS. Although our 
findings are promising, the evidence was confined to 3 studies with a very 
limited overall number of treated patients in this systematic review. 
 
4.2 Findings in the context of existing evidence  
The endocannabinoid system is involved in regulation of LUT function, possibly 
at several levels of the micturition pathway (9). Studies in experimental animal 
models have demonstrated the role of the cannabinoid receptors in sensory 
signalling and afferent bladder functions, as well as a possible modulatory effect 
on cholinergic nerves (19). Fatty acid amide hydrolase (FAAH), which degrades 
endocannabinoids and fatty acid amides, is present both in the bladder mucosa 
and the central nervous system controlling lower urinary tract function. Inhibition 
of FAAH in rat models has been shown to be associated with a modulation of 
cannabinoid type 1 (CB1) and type 2 (CB2) receptors in the spinal cord. In 
addition, endogenous spinal cannabinoid receptor ligands seem to be involved 
in the regulation of normal micturition and detrusor overactivity (9, 20). 
Cannabis is one of the most popular recreational drugs worldwide and it is 
speculated that 178 million people in the age group 15 to 64 years have used it 
at least once in the year 2012 (10). There are approximately 60 
pharmacologically active compounds extracted from the marijuana plant and the 
most popular is THC with psychoactive effects that are related to the 
concentration in the applied preparation (21). Because of the delay in onset of 
effect and narrow therapeutic window with resultant predilection for adverse 
effects, THC is administered in combination with another phytocannabinoid, 
such as CBD (22). Over the years, there has been a growing interest in the 
medical use of cannabis in treating disease and alleviating symptoms. 
Summarizing RCTs to assess the benefits and adverse events of cannabinoids, 
indicates that there is moderate-quality evidence supporting prescription 
cannabinoids as an effective and safe treatment of chronic neuropathic or 
cancer pain, sleep disorders and spasticity due to MS (10, 23). However, a 
statistical significance was not reached in any of the clinical trials. Nevertheless, 
cannabinoids are particular interesting because of the favourable safety profile 
as severe side effects are very rare. 
 
4.3 Implications for research  
Prescription cannabinoids are becoming a well-established pharmacological 
treatment for pain and other diseases with a favourable safety profile (10). The 
preliminary data summarized in this systematic review suggests potential 
benefits of cannabinoids for treating NLUTD in both female and male patients 
with MS and therefore further clinical trials are warranted. Appropriately 
designed multicentric RCTs are necessary to assess validated disease- and 
condition-specific quality of life data, urodynamic findings, short-, medium- and 
long-term outcomes, safety, as well as cost-effectiveness issues. 
Despite many animal studies on cannabinoids and their function, the 
mechanism of action is not yet fully understood and in particular the effects of 
cannabinoids for treating NLUTD remain to be elucidated. Hence, further animal 
studies addressing the potential mechanism of action of cannabinoids for 
treating NLUTD are warranted. 
 
4.4 Implications for practice 
The progressive nature of the course of disease in MS influences NLUTD and 
thereby impacts the effect of therapy (1). Thus, cannabinoids might be 
successful at the beginning in a patient with MS but lose efficacy as the disease 
progresses. Nevertheless, cannabinoids open another therapeutic avenue for 
managing NLUTD in patients with MS. The safety profile is favourable and 
cannabinoids are devoid of the adverse effects associated with other more 
commonly used agents such as blurred vision or constipation, which are 
particularly relevant in neurological patients. Moreover, this treatment is not 
associated with a risk for voiding dysfunction in contrast to most of the other 
therapeutic options and is particularly attractive to patients with MS where 
catheterisation and associated complications are a real concern. The general 
practitioner and/or neurologist may initiate the neuro-urological treatment 
considering that the risk of developing upper urinary tract damage and renal 
failure is much lower in patients with slowly progressive non-traumatic 
neurological disorders such as MS and Parkinson’s disease than in those with 
spinal cord injury or spina bifida (1). The treatment goals of cannabinoids vary 
between different neurological disorders. Thus, dose- and disease-specific 
studies are warranted and continuous versus on demand medication has to be 
further assessed. In addition, cannabinoids might be considered as a treatment 
improving different quality of life issues of the patient with MS including NLUTD. 
Taking into account the potential of cannabinoids in medical use (10), it seems 
worth to try it out before more invasive treatments are established. 
 
4.5 Limitations of this study 
Although this report represents, to the best of our knowledge, the first study that 
systematically reviewed and synthesized all available evidence of cannabinoids 
for treating NLUTD in patients with MS, there are limitations that should be 
addressed. The number of included articles, the number of investigated patients 
and the follow-up was very limited. Moreover, the severity of MS and the 
NLUTD has not been reported. In addition, the missing control group of the 
open label study was replaced by a norm-control group generated by the mean 
values of the two control groups from the RCTs for statistical analysis. In the 
absence of robust evidence there is a trade-off between the level of 
methodological rigor of an analysis and the efficiency. Using the base-rate of 
the two RCTs allowed us to incorporate the single-arm study. In view of the fact 
that any result derived from 2 or 3 studies will be exploratory, we decided to 
stick to this approach. Standard deviations for baseline and follow-up 
measurements were missing in most outcome measures and the between-study 
heterogeneity was substantial. More detailed methodological study limitations 
are described in Web supplement 3. 
  
5. Conclusions 
The currently available evidence implies that cannabinoids may be effective and 
safe for treating NLUTD in patients with MS. However, although we identified 2 
RCTs, the reported outcomes, number of investigated patients and follow-up 
were very limited and the between-study heterogeneity was substantial. Thus, 
our systematic review, although suggesting that the treatment with 
cannabinoids seems to be a promising option for NLUTD in patients with MS, 
has shown the urgent need for well-designed, adequately sampled and 
powered RCTs to reach definitive conclusions. 
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